Skip to main content
. 2017 Dec 28;9(10):8801–8809. doi: 10.18632/oncotarget.23753

Figure 3. Gallium DOTATATE scan sowing disease burden at the time of progression on immune checkpoint inhibitor therapy (case 1).

Figure 3